Please login to the form below
Dementia Discovery Fund
This page shows the latest Dementia Discovery Fund news and features for those working in and with pharma, biotech and healthcare.
Bicycles Therapeutics enters dementia discovery with venture capital fund
Ambitious UK biotech expands research scope. UK biotech rising star Bicycle Therapeutics has announced a new alliance with the Dementia Discovery Fund (DDF) to use its novel platform to develop new ... A special DDF panel of neuroscientists and experts
Latest news
-
Daily Brief: Dementia Fund hits $350m mark, hard Brexit could cost £100bn in trade and troublesome results for Pfizer’s Ibrance
The Dementia Discovery Fund (DDF) confirmed yesterday that it had raised £250m ($350m), boosted by a $60m investment from US non-profit organisation AARP, which aims to help older people live ... The fundraising far exceeded its initial target of $200m (
-
British Business Bank sets up £2.5bn fund for ‘unicorn’ firms
A new UK government-backed investment vehicle to provide long-term capital for British businesses has been launched, with a fund backing dementia drug developers among the first to benefit. ... The Dementia Discovery Fund is one of two VCs given funding
-
Pfizer drops neuroscience R&D, cutting 300 jobs
It will also set up a dedicated venture capital fund to invest in other companies carrying out neuroscience R&D and “support continued efforts to advance the field”. ... Pfizer is already one of the founder members of the cross-company Dementia
-
Woodford investment pushes Dementia Discovery Fund to £100m
Fund aims to back 40 projects over its 15-year term. Thanks to a £15m pledge from Neil Woodford's investment group, the public-private Dementia Discovery Fund (DDF) has now ... therapies. The DDF's chief scientific officer - former Takeda drug discovery
-
GSK and J&J back new UK dementia discovery fund
Pharma giants collaborate with government to find new treatments. GlaxoSmithKline, Johnson &Johnson and Pfizer have signed up to support a new UK government dementia discovery fund. ... The fund will work with universities, academic institutes and the
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Detecting Alzheimer’s ahead of a cure
A new company has been created from Alzheimer’s Research UK’s Drug Discovery Alliance, which will build on the work of the charity’s UCL Drug Discovery Institute. ... This newly formed biotech company, named AstronauTx, has recently received £6.5m
-
Brain power: fresh approaches to Alzheimer’s drug discovery
The venture capital approach to dementia research. The Dementia Discovery Fund is a venture capital fund focused on discovering and developing novel therapies for dementia, first set up in October 2015. ... Angus Grant, CEO of the Dementia Discovery Fund,
-
30 Women Leaders in UK Healthcare (part 2)
In the meantime, she is challenging not just the accepted ways of conducting drug discovery, but also some of the male behaviour that can mar the working environment. ... the UK’s new Dementia Discovery Fund (DDF) and serves on the DDF Investment
-
The world is our laboratory
This year, through J&J Innovation, we will invest $10m into the UK government-led Global Dementia Discovery Fund, supporting innovative research into the area. ... This was set up in 2013 to identify innovative solutions for dementia care.
-
Pharma deals in March 2015
This month saw GSK invest $25m, J&J $10m and the UK Government $22m into the Dementia Discovery fund, a joint initiative also including Lilly, Biogen and Pfizer to research treatments
More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest appointments
-
New hires at EMA, Gilead and BeiGene
Most recently, Grant was chief executive officer of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Forecasting in Forgotten Markets
To help address a lack of investment in novel dementia science a new £100M Dementia Discovery Fund ( ) was launched towards the end of last year. ... Managed by SV Life Sciences the fund is focused primarily on Phase I and II research and aims to help
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Account Director
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Lead Copywriter
-
Competitive
- Nucleus Global announces a trio of promotions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer introduces new logo in a ‘shift from commerce to science’
- New study identifies drugs that are safe to use in COVID-19 treatment
- PHE study finds people who have had COVID-19 can still transmit the virus
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
